Study the Expression of CD10 in Prostate Carcinoma and its Correlation with Various Clinicopathological Parameters

Document Type: Original Research

Authors

1 Junior Resident, M.B.B.S, Dept. of Pathology, Pt. BD Sharma, PGIMS Rohtak, Haryana, India

2 Professor, M.B.B.S, M.D, Dept. of Pathology, Pt BD Sharma, PGIMS Rohtak, Haryana, India

3 Senior Resident, M.B.B.S, M.D, DNB, Dept. Of Pathology, Pt BD Shrama, PGIMS Rohtak, Haryana, India

4 Professor & Head, M.B.B.S, M.S, M.Ch. Dept. of Urology, Pt. BD Sharma, PGIMS Rohtak, Haryana, India

5 Professor & Head, M.B.B.S, M.D, Dept. of Pathology, Pt BD Sharma, PGIMS Rohtak, Haryana, India

10.30699/ijp.14.2.135

Abstract

Background and Objective: Adenocarcinoma of the prostate is the second most common cause of cancer. The loss of CD10 is a common early event in human prostate cancer and is seen in lower Gleason Score malignancies while increased and altered expression is seen in high Gleason Score tumors, lymph nodes and bone metastasis.
Material and Methods: This was a prospective observational study conducted on 75 patients suspected to have prostate cancer. Immunohistochemical profile was assessed for PSA, AMACR and CD10 immunostaining. The intensity of CD10 expression and pattern of CD10 staining of tumor cells was evaluated.
 Results: The patients were in age group of 50-90 years with a mean age of 70.97 ± 9.51 years. As the Grade Group/Gleason Score increased, the number of cases showing negative expression decreased and the pattern of expression changed from membranous to cytoplasmic to both types of expression. As the serum PSA levels increased the intensity of expression changed from focally positive to diffusely positive. The pattern of expression also changed from membranous to cytoplasmic to both (membranous + cytoplasmic) types of expression with an increase in PSA levels.
Conclusion: By immunohistochemical analysis we can identify CD10 positive tumors, which may warrant more aggressive initial therapy. A number of drugs against CD10 are available based on which potential targeted therapies could be formulated.

Keywords

Main Subjects


References

  1. Trapman J. Molecular mechanisms of prostate cancer. Eur J Cancer. 2001;37:S119-80.
    https://doi.org/10.1016/S0959-8049(01)80013-7
  2. Epstein J. The lower urinary tract and male genital system. In:Kumar, Abbas, Fausto, editors. Robbins and Cotran Pathologic Basis of Diseases. 8th edition. Philadelphia:Saunders;2010.p.993-1002.
    https://doi.org/10.1016/B978-1-4377-0792-2.50026-2
  3. Cheetan PJ. Markers in prostate cancer. In: Tiwari AK, Whelan P, Graham JD, editors. Prostate cancer: Diagnosis and clinical management. 1st ed. John wiley and sons; 2014.p.49-71.
    https://doi.org/10.1002/9781118347379.ch4
  4. Bostwick D. Prostate specific antigen, current role in diagnostic pathology of prostate cancer. Am J Pathol. 1994;102:S31-7.
  5. Epstein JI. A new contemporary prostate cancer grading system: message to the Italian pathologists. Pathologica. 2015;107:205-7.
    https://doi.org/10.1111/pin.12353
  6. Tawfic S, Niehans GA, Manivel JC. The pattern of CD10 expression in selected pathologic entities of the prostate gland. Hum Pathol. 2003;34:450-6.
    https://doi.org/10.1016/S0046-8177(03)00077-7
  7. Era M, True L, Siegel A, Porter M, Sherertz T, Liu A. Differential expression of CD10 in prostate cancer and its clinical implication. BMC Urology. 2007;1471-90.
  8. Albrecht M, Mittler A, Wilhelm B, Lundwall Å, Lilja H, Aumüller G et al. Expression and immunolocalization of neutral endopeptidase in prostate cancer. Eur Urol. 2003;44:415-22.
    https://doi.org/10.1016/S0302-2838(03)00322-1
  9. Saranya D. Analysis of immunohistochemical expression of CD10 in the malignant lesions of prostate. IOSR-J of Dental and Med Sci. 2017;16:78-82.
  10. Vlachostergios PJ, Foteini K, Grigorios K, George M, Anna P, Loannis A et al. CD10 and endothelin 1 are inversely expressed in early prostate cancer and predict  PSA failure after radical prostatectomy. J Cancer Sci Ther S1. 2011;1948-56.
    https://doi.org/10.4172/1948-5956.S1-005
  11. Osman I, Yee H, Taneja SS, Levinson B, Chang C, Nobert C et al. Neutral endopeptidase protein expression and prognosis in localized prostate cancer. Clin Cancer Res. 2004;10:4096-100.
    https://doi.org/10.1158/1078-0432.CCR-04-0120
  12. Fleischmann A, Schlimm T, Huland H, Kollermann J, Simon P, Mirlacher M et al. Distinct subcellular expression patterns of neutral endopeptidase in prostate cancer predict diverging clinical courses in surgically treated patients. Clinical cancer research. 2008;14:7838-42.
    https://doi.org/10.1158/1078-0432.CCR-08-1432